{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:09:18Z","timestamp":1764601758172},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and aim<\/jats:title><jats:p>Galectins have been recently tackled by many researchers in the field of cancer due to their role in tumorigenesis, disease progression, and metastasis. Thus, they are currently involved in biomarkers research on several types of cancer. In ovarian cancers, few studies were carried out to evaluate galectins expression profiling. Hence, our present study was executed to evaluate the mRNA expression of galectins -1, -3, -4, -8, and -9 in epithelial ovarian cancers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty-six tumor samples of ovarian carcinomas were analyzed for mRNA expression using qRT-PCR, and fold-changes were calculated in comparison to tissue samples of 26 women with normal ovaries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results of the present paper emphasize the importance of galectins as predictors for targeted therapy.<jats:italic>LGALS1<\/jats:italic>,<jats:italic>LGALS3<\/jats:italic>,<jats:italic>LGALS4<\/jats:italic>,<jats:italic>LGALS8<\/jats:italic>, and<jats:italic>LGALS9<\/jats:italic>were found to be mostly overexpressed in ovarian carcinoma patients with the following percentage: 78.6%, 92.9%, 66.1%, 87.5%, and 85.7% respectively. Moreover, galectins -3 and -9 were found to be significantly elevated with lymph node metastasis (<jats:italic>p<\/jats:italic>= 0.044 and<jats:italic>p<\/jats:italic>= 0.011). Also, upregulation of galectin-1 and -9 were statistically significant in stages IIB, IIC, and IIIB (<jats:italic>p<\/jats:italic>= 0.002) in FIGO staging. CA19.9 is positively correlated to galectin-4 expression (<jats:italic>p<\/jats:italic>= 0.039).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings strengthen the role of galectins in carcinogenesis, disease progression, and lymphnode metastasis in ovarian carcinomas. And since these galectins are mostly overexpressed, they could be promising markers for targeted therapy to reduce disease progression and metastasis process.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12957-022-02738-4","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T06:03:42Z","timestamp":1662012222000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of galectins -1, -3, -4, -8, and -9 expression in ovarian carcinoma patients with clinical implications"],"prefix":"10.1186","volume":"20","author":[{"given":"Radwa Mansour","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athar","family":"Emam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud M.","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel-Mageed Ismail","family":"Abdel-Mageed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Abdelhafeez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham","family":"Helwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"2738_CR1","unstructured":"(IARC) WHOIAfRoC. GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. 2020. http:\/\/globocaniarcfr\/Pages\/fact_sheets_cancer.aspx; https:\/\/gco.iarc.fr\/today\/home. Accessed 20 Sept 2021."},{"issue":"3","key":"2738_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2738_CR3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2738_CR4","first-page":"88","volume":"2","author":"AH Ebrahim","year":"2014","unstructured":"Ebrahim AH, Alalawi Z, Mirandola L, et al. Galectins in cancer: carcinogenesis, diagnosis and therapy. Ann Transl Med. 2014;2(9):88.","journal-title":"Ann Transl Med"},{"issue":"2-3","key":"2738_CR5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0304-4165(02)00315-X","volume":"1572","author":"A Danguy","year":"2002","unstructured":"Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta. 2002;1572(2-3):285\u201393.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2738_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ijgo.13471","volume":"152","author":"V Pergialiotis","year":"2021","unstructured":"Pergialiotis V, Papoutsi E, Androutsou A, et al. Galectins-1, -3, -7, -8 and -9 as prognostic markers for survival in epithelial ovarian cancer: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2021;152(3):299\u2013307.","journal-title":"Int J Gynaecol Obstet"},{"key":"2738_CR7","doi-asserted-by":"publisher","unstructured":"Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients. Int J Mol Sci. 2017;18(6):1230. https:\/\/doi.org\/10.3390\/ijms18061230.","DOI":"10.3390\/ijms18061230"},{"issue":"4","key":"2738_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/0092-8674(94)90498-7","volume":"76","author":"SH Barondes","year":"1994","unstructured":"Barondes SH, Castronovo V, Cooper DN, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell. 1994;76(4):597\u20138.","journal-title":"Cell."},{"issue":"4","key":"2738_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s13402-017-0317-9","volume":"40","author":"R Helwa","year":"2017","unstructured":"Helwa R, Heller A, Knappskog S, Bauer AS. Tumor cells interact with red blood cells via galectin-4 - a short report. Cell Oncol (Dordr). 2017;40(4):401\u20139.","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"2738_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00262-015-1788-z","volume":"65","author":"S Chawla","year":"2016","unstructured":"Chawla S, Warren TA, Wockner LF, et al. Galectin-1 is associated with poor prognosis in patients with cutaneous head and neck cancer with perineural spread. Cancer Immunol Immunother. 2016;65(2):213\u201322.","journal-title":"Cancer Immunol Immunother"},{"issue":"19","key":"2738_CR11","doi-asserted-by":"publisher","first-page":"27584","DOI":"10.18632\/oncotarget.8488","volume":"7","author":"YL Hsu","year":"2016","unstructured":"Hsu YL, Hung JY, Chiang SY, et al. Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2\/kynurenine axis. Oncotarget. 2016;7(19):27584\u201398.","journal-title":"Oncotarget."},{"issue":"9","key":"2738_CR12","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.18632\/oncotarget.1219","volume":"4","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, Hwang JA, Ro JY, Lee YS, Chun KH. Galectin-7 is epigenetically-regulated tumor suppressor in gastric cancer. Oncotarget. 2013;4(9):1461\u201371.","journal-title":"Oncotarget."},{"issue":"7","key":"2738_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131307","volume":"10","author":"M Labrie","year":"2015","unstructured":"Labrie M, Vladoiu M, Leclerc BG, et al. A mutation in the carbohydrate recognition domain drives a phenotypic switch in the role of galectin-7 in prostate cancer. PLoS One. 2015;10(7):e0131307.","journal-title":"PLoS One"},{"issue":"1-2","key":"2738_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2152\/jmi.55.127","volume":"55","author":"M Sakaki","year":"2008","unstructured":"Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO. Serum level of galectin-3 in human bladder cancer. J Med Investig. 2008;55(1-2):127\u201332.","journal-title":"J Med Investig"},{"issue":"10","key":"2738_CR15","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.1007\/s13277-015-3513-0","volume":"36","author":"AA El Leithy","year":"2015","unstructured":"El Leithy AA, Helwa R, Assem MM, Hassan NH. Expression profiling of cancer-related galectins in acute myeloid leukemia. Tumour Biol. 2015;36(10):7929\u201339.","journal-title":"Tumour Biol"},{"key":"2738_CR16","doi-asserted-by":"publisher","unstructured":"Wdowiak K, Francuz T, Gallego-Colon E, Ruiz-Agamez N, Kubeczko M, Grocho\u0142a I, Wojnar J. Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives. Int J Mol Sci. 2018;19(1):210. https:\/\/doi.org\/10.3390\/ijms19010210.","DOI":"10.3390\/ijms19010210"},{"issue":"33","key":"2738_CR17","doi-asserted-by":"publisher","first-page":"20807","DOI":"10.1016\/S0021-9258(17)31891-4","volume":"269","author":"SH Barondes","year":"1994","unstructured":"Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994;269(33):20807\u201310.","journal-title":"J Biol Chem"},{"issue":"2","key":"2738_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10585-012-9516-y","volume":"30","author":"JR Newton-Northup","year":"2013","unstructured":"Newton-Northup JR, Dickerson MT, Ma L, Besch-Williford CL, Deutscher SL. Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide. Clin Exp Metastasis. 2013;30(2):119\u201332.","journal-title":"Clin Exp Metastasis"},{"issue":"7","key":"2738_CR19","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.biomaterials.2011.12.007","volume":"33","author":"Y Yang","year":"2012","unstructured":"Yang Y, Zhou Z, He S, et al. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates. Biomaterials. 2012;33(7):2260\u201371.","journal-title":"Biomaterials."},{"key":"2738_CR20","doi-asserted-by":"publisher","unstructured":"Cadenas J, Pors SE, Nikiforov D, Zheng M, Subiran C, B\u00f8tkj\u00e6r JA, Mamsen LS, Kristensen SG, Andersen CY. Validating Reference Gene Expression Stability in Human Ovarian Follicles, Oocytes, Cumulus Cells, Ovarian Medulla, and Ovarian Cortex Tissue. Int J Mol Sci. 2022;23(2):886. https:\/\/doi.org\/10.3390\/ijms23020886.","DOI":"10.3390\/ijms23020886"},{"issue":"10","key":"2738_CR21","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s10815-018-1263-9","volume":"35","author":"DA Nikishin","year":"2018","unstructured":"Nikishin DA, Filatov MA, Kiseleva MV, et al. Selection of stable expressed reference genes in native and vitrified\/thawed human ovarian tissue for analysis by qRT-PCR and Western blot. J Assist Reprod Genet. 2018;35(10):1851\u201360.","journal-title":"J Assist Reprod Genet"},{"issue":"24","key":"2738_CR22","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.7150\/jca.23628","volume":"9","author":"M Chetry","year":"2018","unstructured":"Chetry M, Thapa S, Hu X, et al. The role of galectins in tumor progression, treatment and prognosis of gynecological cancers. J Cancer. 2018;9(24):4742\u201355.","journal-title":"J Cancer"},{"issue":"Suppl 10","key":"2738_CR23","doi-asserted-by":"publisher","first-page":"x111","DOI":"10.1093\/annonc\/mds300","volume":"23","author":"J Prat","year":"2012","unstructured":"Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23(Suppl 10):x111\u20137.","journal-title":"Ann Oncol"},{"key":"2738_CR24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.3389\/fimmu.2020.01820","volume":"11","author":"S Caputo","year":"2020","unstructured":"Caputo S, Grioni M, Brambillasca CS, et al. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. Front Immunol. 2020;11:1820.","journal-title":"Front Immunol"},{"issue":"4","key":"2738_CR25","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20165356","volume":"50","author":"M Li","year":"2017","unstructured":"Li M, Feng YM, Fang SQ. Overexpression of ezrin and galectin-3 as predictors of poor prognosis of cervical cancer. Braz J Med Biol Res. 2017;50(4):e5356.","journal-title":"Braz J Med Biol Res"},{"key":"2738_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ijbiomac.2019.09.118","volume":"142","author":"YS Li","year":"2020","unstructured":"Li YS, Li XT, Yu LG, Wang L, Shi ZY, Guo XL. Roles of galectin-3 in metabolic disorders and tumor cell metabolism. Int J Biol Macromol. 2020;142:463\u201373.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"2738_CR27","first-page":"4907","volume":"15","author":"J Zhang","year":"2018","unstructured":"Zhang J, Deng G, Qiao L, et al. Effect of galectin-3 on vasculogenic mimicry in esophageal cancer cells. Oncol Lett. 2018;15(4):4907\u201311.","journal-title":"Oncol Lett"},{"issue":"6","key":"2738_CR28","first-page":"2544","volume":"26","author":"MM Abdelfattah","year":"2021","unstructured":"Abdelfattah MM, Assem MM, El Leithy AA, Allam RM, Hassan NM, Helwa R. Galectins in AML: gene expression profiling with clinical emphasis. JBUON. 2021;26(6):2544\u201352.","journal-title":"JBUON."},{"issue":"9","key":"2738_CR29","first-page":"1093","volume":"29","author":"MT Elola","year":"2014","unstructured":"Elola MT, Ferragut F, Cardenas Delgado VM, et al. Expression, localization and function of galectin-8, a tandem-repeat lectin, in human tumors. Histol Histopathol. 2014;29(9):1093\u2013105.","journal-title":"Histol Histopathol"},{"issue":"3","key":"2738_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1136\/gut.50.3.392","volume":"50","author":"N Nagy","year":"2002","unstructured":"Nagy N, Bronckart Y, Camby I, et al. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut. 2002;50(3):392\u2013401.","journal-title":"Gut."},{"issue":"3","key":"2738_CR31","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1007\/s12032-008-9122-7","volume":"26","author":"S Savin","year":"2009","unstructured":"Savin S, Cvejic D, Jankovic M, Isic T, Paunovic I, Tatic S. Evaluation of galectin-8 expression in thyroid tumors. Med Oncol. 2009;26(3):314\u20138.","journal-title":"Med Oncol"},{"key":"2738_CR32","doi-asserted-by":"publisher","unstructured":"Schulz H, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U, Schmoeckel E. Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9. Int J Mol Sci. 2018;19(1):323. https:\/\/doi.org\/10.3390\/ijms19010323.","DOI":"10.3390\/ijms19010323"},{"issue":"2","key":"2738_CR33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s13402-013-0124-x","volume":"36","author":"SW Kim","year":"2013","unstructured":"Kim SW, Park KC, Jeon SM, et al. Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer. Cell Oncol (Dordr). 2013;36(2):169\u201378.","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"2738_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065957","volume":"8","author":"AI Belo","year":"2013","unstructured":"Belo AI, van der Sar AM, Tefsen B, van Die I. Galectin-4 reduces migration and metastasis formation of pancreatic cancer cells. PLoS One. 2013;8(6):e65957.","journal-title":"PLoS One"},{"issue":"6","key":"2738_CR35","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/jcp.2005.034223","volume":"60","author":"VA Heinzelmann-Schwarz","year":"2007","unstructured":"Heinzelmann-Schwarz VA, Scolyer RA, Scurry JP, et al. Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries. J Clin Pathol. 2007;60(6):622\u20136.","journal-title":"J Clin Pathol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-022-02738-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-022-02738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T12:59:56Z","timestamp":1701003596000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-022-02738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2738"],"URL":"https:\/\/doi.org\/10.1186\/s12957-022-02738-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"15 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Ain Shams University, Faculty of Medicine ethical committee. A written consent was taken from each patient or their legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}